Accenture released a new report on product launches in the pharmaceutical industry, based on a survey of 8,000 patients in France, Germany, the UK, and the U.S., across eight therapeutic areas-immunology, cardiology, pulmonology, neurology, oncology, rheumatology, endocrinology, and eye disease. The report is designed to help pharma companies understand what will help enable them to launch new treatments successfully in a market characterized by more-complex specialty therapeutics, rising costs, and an intensified focus on value and outcomes.
Findings in the report include that brands are not major influencing factors when patients consider new pharmaceutical products; more than two-thirds (69%) of patients surveyed said the product’s benefits (i.e., treatment outcomes) are more important than the brand itself, with less than one-third (31%) citing a strong affinity to brands in a healthcare setting.
Based on survey findings, the report offers two major recommendations for pharma companies, 1) bring an outcome, not just a product, to market and 2) make it personal and precise.
View the full report here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.